Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China

CONCLUSION: The triple therapy (FF/UMEC/VI) is more affordable than dual therapy (UMEC/VI) when compared to China's three times GDP per capita criterion.PMID:38621548 | DOI:10.1016/j.rmed.2024.107632

Source: Respiratory Care - April 15, 2024 Category: Respiratory Medicine Authors: Yuan Zhou Shujing Duan Lei Zhang Fangchen Peng Source Type: research